Phadia First Company To Receive FDA Clearance Of Recombinant Allergen Component Tests

Wednesday, Sep. 7th 2011 6:40 AM

Phadia, the global leader in allergy and autoimmunity diagnostics, today announced the FDA clearance of recombinant ImmunoCAP® Allergen Components for marketing in the United States. The FDA clearance applies to all of Phadia’s instrument platforms.

VN:F [1.9.22_1171]
Rating: 5.0/5 (1 vote cast)
VN:F [1.9.22_1171]
Rating: 0 (from 0 votes)
Phadia First Company To Receive FDA Clearance Of Recombinant Allergen Component Tests, 5.0 out of 5 based on 1 rating
Posted on Wednesday, Sep. 7th 2011 6:40 AM | by Share of Cost | in Share of Cost | No Comments »

Leave a Reply

You must be logged in to post a comment.